Patient characteristics
| Characteristic . | No. of patients (N = 101) . |
|---|---|
| Age (range), y | 48 (21-72) |
| Sex, n (%) | |
| Male | 64 (63) |
| Female | 37 (37) |
| Disease, n (%) | |
| AML | 61 (60) |
| CML | 25 (25) |
| MDS | 14 (14) |
| MPN | 1 (1) |
| Disease stage, n (%) | |
| CR/CP | 48 (48) |
| Not in CR/CP | 53 (52) |
| Conditioning intensity, n (%) | |
| Myeloablative | 71 (71) |
| Reduced intensity | 30 (29) |
| Donor type, n (%) | |
| HLA-matched related donor | 72 (72) |
| HLA-matched unrelated donor | 29 (28) |
| Graft source, n (%) | |
| Peripheral blood stem cells | 68 (67) |
| Bone marrow | 33 (33) |
| Sex mismatch, n (%) | |
| Female donor into male recipient | 28 (28) |
| Male donor into female recipient | 19 (19) |
| Characteristic . | No. of patients (N = 101) . |
|---|---|
| Age (range), y | 48 (21-72) |
| Sex, n (%) | |
| Male | 64 (63) |
| Female | 37 (37) |
| Disease, n (%) | |
| AML | 61 (60) |
| CML | 25 (25) |
| MDS | 14 (14) |
| MPN | 1 (1) |
| Disease stage, n (%) | |
| CR/CP | 48 (48) |
| Not in CR/CP | 53 (52) |
| Conditioning intensity, n (%) | |
| Myeloablative | 71 (71) |
| Reduced intensity | 30 (29) |
| Donor type, n (%) | |
| HLA-matched related donor | 72 (72) |
| HLA-matched unrelated donor | 29 (28) |
| Graft source, n (%) | |
| Peripheral blood stem cells | 68 (67) |
| Bone marrow | 33 (33) |
| Sex mismatch, n (%) | |
| Female donor into male recipient | 28 (28) |
| Male donor into female recipient | 19 (19) |